



Supplemental Figure 1




Supplemental Figure 2









A



B



Supplemental Figure 3



1 **Supplemental Figure Legends**

2 **Supplemental Figure 1: miR-24-3p knockout mice do not display**  
3 **spontaneous colitis.** After collection of feces from both male and  
4 female adult mice a Lipocalin-2 ELISA was performed. The positive  
5 control is feces from a wild-type mouse with acute DSS colitis. n =  
6 10 mice/group. Mean  $\pm$  SD.

7 **Supplemental Figure 2: miR-24-3p inhibition does not affect the**  
8 **onset of DSS colitis.** (A) Representative H&E stained swiss rolled  
9 colons from day 5 control inhibitor and miR-24-3p inhibitor treated  
10 mice. Scale bars = 0.25 mm. (B) The average total, infiltrate, and  
11 ulceration scores from 2 double blinded reviewers of day 5 inhibitor  
12 treated mice. Mean  $\pm$  SD. n = 8 mice / group.

13 **Supplemental Figure 3: miR-24-3p overexpression or inhibition**  
14 **does not influence the protein levels of BCL-2 or BAX.** (A,B)  
15 Western blots and densitometric analysis of BCL-2 (A) and BAX (B)  
16 after overnight treatment with inhibitors and a 4 hr treatment with  
17 staurosporine. 3 independent experiments. Mean  $\pm$  SEM. (C,D)  
18 Western blots and densitometric analysis of BCL-2 (A) and BAX (B)  
19 after overnight treatment with miRNA mimetics and a 4 hr treatment  
20 with staurosporine. 3 independent experiments. Mean  $\pm$  SEM.

21